<DOC>
	<DOCNO>NCT00002489</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat child non-testicular malignant germ cell tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Non-testicular Malignant Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy cyclophosphamide , carboplatin , etoposide patient non-testicular malignant germ cell tumor . II . Improve quality life patient shorten length treatment extent initial surgical resection . III . Determine whether histologic subtypes prognostic significance . IV . Determine efficacy short term chemotherapy patient population . V. Determine role second look surgery predict curability non testicular germ cell tumor . VI . Determine role dose intensification cyclophosphamide introduction doxorubicin , methotrexate , dactinomycin patient partial response , response , progressive disease time second look surgery . OUTLINE : Patients undergo treatment Regimen A consist surgical resection tumor appropriate disease follow chemotherapy cyclophosphamide IV 20 minute day 1 , carboplatin IV day 2 , etoposide IV day 2-4 . Patients receive filgrastim ( G-CSF ) subcutaneously ( SQ ) daily begin 24-48 hour follow last dose etoposide continue 14 day blood count recover ( total 28 day ) . Chemotherapy repeat every 3 week 4 course absence disease progression . At week 11 , patient undergo second look surgery evaluate response resect residual disease . Patients residual disease receive therapy . Patients good partial response response receive salvage chemotherapy Regimen B . Patients receive salvage chemotherapy Regimen B consist dactinomycin IV day 1-3 , doxorubicin IV vincristine IV continuously day 1-3 , G-CSF SQ daily begin 24-48 hour follow last dose vincristine continue 14 day blood count recover . At week 3 , patient receive cyclophosphamide IV day 1-2 , vincristine IV doxorubicin IV continuously day 1-3 G-CSF previously give Regimen B . At week 6 , patient receive methotrexate IV day 1 leucovorin calcium orally IV every 6 hour 3 day , begin 16 hour completion methotrexate . At week 8 , salvage chemotherapy repeat additional course . Patients achieve complete response follow salvage chemotherapy receive therapy . Patients response remove study . PROJECTED ACCRUAL : A maximum 25 patient accrue study 6 year .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Malignant germ cell tumor follow stage primary site : Stage II/III/IV ovarian tumor Grade II/III immature glial teratoma Stage II/III/IV mediastinal tumor Stage II/III/IV presacral tumor tumor primary sit No intracranial testicular primary site PATIENT CHARACTERISTICS : Age : Child Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage II ovarian germ cell tumor</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>ovarian teratoma</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
</DOC>